CTXR
Citius Pharmaceuticals Inc
NASDAQ: CTXR · HEALTHCARE · BIOTECHNOLOGY
$0.70
+16.96% today
Updated 2026-04-30
Market cap
$17.23M
P/E ratio
—
P/S ratio
4.37x
EPS (TTM)
$-2.46
Dividend yield
—
52W range
$1 – $2
Volume
0.7M
WallStSmart proprietary scores
27
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+2.5
Profitability
F4.0
Valuation
C4/9
Piotroski F-Score
Moderate
-2.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$6.00
+762.07%
12-Month target
—
—
Intrinsic (DCF)
$0.76
Margin of safety
-18.33%
0 Strong Buy1 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Debt/equity 0.01x — low leverage
Risks
- Altman Z -2.81 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-13.01M
- 18.33% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $3.94M |
| Net income | $-33.64M | $-32.54M | $-39.14M | $-37.43M | $-8.22M |
| EPS | — | — | — | — | $-2.46 |
| Free cash flow | $-28.36M | $-29.06M | $-28.20M | $-26.55M | $-13.01M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Citius Pharmaceuticals Inc trades at $0.70. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -2.81, it sits in the distress. TTM revenue stands at $3.94M. Our DCF model estimates intrinsic value at $0.76.
Frequently asked questions
What is Citius Pharmaceuticals Inc's stock price?
Citius Pharmaceuticals Inc (CTXR) trades at $0.70.
Is Citius Pharmaceuticals Inc overvalued?
Smart Value Score 27/100 (Grade F, Strong Sell). DCF value $0.76.
What is the price target of Citius Pharmaceuticals Inc (CTXR)?
The analyst target price is $6.00, representing +762.1% upside from the current price of $0.70.
What is the intrinsic value of Citius Pharmaceuticals Inc (CTXR)?
Based on our DCF model, intrinsic value is $0.76, a -18.3% margin of safety versus $0.70.
What is Citius Pharmaceuticals Inc's revenue?
TTM revenue is $3.94M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
-2.81 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.37x
ROE-47.80%
Beta1.38
50D MA$0.81
200D MA$1.10
Shares out0.02B
Float0.02B
Short ratio—
Avg volume0.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—